ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "DMARDs and combination therapies"

  • Abstract Number: 1055 • 2013 ACR/ARHP Annual Meeting

    Discontinuation Rates In Patients With RA Of Triple Disease Modifying Antirheumatic Therapy

    Sofia Pedro1, Frederick Wolfe1, Hawre Jalal2 and Kaleb Michaud3, 1National Data Bank for Rheumatic Diseases, Wichita, KS, 2Health Polisy and Management, University of Minnesota, Minneapolis, MN, 3Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Drug discontinuation rates are measures of effectiveness and are needed in health economic models. While a recent RCT demonstrated statistical equivalence of efficacy with…
  • Abstract Number: 1300 • 2012 ACR/ARHP Annual Meeting

    Characteristics Associated with Biologic Initiation As Monotherapy Versus Combination Therapy in Patients with Rheumatoid Arthritis (RA) in a US Registry Population

    Dimitrios A. Pappas1, George W. Reed2, Katherine C. Saunders3, Ani John4, Ashwini Shewede4, Jenny Devenport5, Jeffrey D. Greenberg6 and Joel M. Kremer7, 1Columbia University, New York, NY, 2University of Massachusetts Medical School, Worcester, MA, 3Corrona, LLC., Southborough, MA, 4Genentech Inc., South San Francisco, CA, 5Genentech, South San Francisco, CA, 6Rheumatology, NYU Hospital for Joint Diseases, New York, NY, 7Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: Approximately one-third of RA patients were prescribed biologic (Bio) monotherapy (MT) i.e. without concomitant disease-modifying anti-rheumatic drugs (DMARD) (Yazici et al., 2008). The purpose…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.